Alnylam Pharmaceuticals Inc (ALNY) — Cash Flow Quality Index

Latest as of December 2025: 0.88x

Alnylam Pharmaceuticals Inc (ALNY) has a Cash Flow Quality Index of 0.88x as of December 2025. Operating cash flow of $163.56 Million is below net income of $186.42 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore ALNY long-term investments to assets to see how much of total assets are deployed in long-term investments.

Cash Flow Quality Index

0.88x
Operating CF / Net Income

Operating Cash Flow

$163.56 Million
USD

Net Income

$186.42 Million
USD

Data as of

Dec 2025
Most recent filing

Alnylam Pharmaceuticals Inc Cash Flow Quality Index (2025–2025)

Historical Cash Flow Quality Index for Alnylam Pharmaceuticals Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Alnylam Pharmaceuticals Inc tangible book value ratio to evaluate the tangible quality of the company's equity base.

Annual Cash Flow Quality Index for Alnylam Pharmaceuticals Inc (2025–2025)

Year-by-year earnings quality comparison for Alnylam Pharmaceuticals Inc. For live market cap and the full company financial profile, see ALNY company net worth.

Year Quality Index Operating CF (USD) Net Income YoY Change
2025 1.67x $524.08 Million $313.75 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.